Cardiovascular disease in HIV-infected patients on highly active antiretroviral therapy;Enfermedad cardiovascular sintomática en pacientes infectados por el virus de la inmunodeficiencia humana que reciben tratamiento antirretroviral de gran actividad

Medicina Clinica

Volumn 122, Issue 8, 2004, Pages 298-300

  Jericó, Carlos ^a   Knobel, Hernando ^a   Carmona, Alexia ^a   Sorli, M Luisa ^a   López Colomés, José Luis ^a   Pedro Botet, Juan ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Antiretroviral therapy; Cardiovascular disease; Cardiovascular risk; HIV infection; Secondary prevention

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; EPIDEMIOLOGICAL DATA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; TREATMENT OUTCOME;

EID: 1942487410     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13058678     Document Type: Article

References (10)

1. Ippolito G, Galati V, Serraino D, Girardi E. The changing picture of the HIV/AIDS epidemic. Ann N Y Acad Sci 2001;946:1-12.
2. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
3. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with immunodeficiency virus infection. Clin Infect Dis 2002;34:98-102.
4. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
5. National Cholesterol Education Program. Third report of the National Cholesterol Education Program on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
6. Dronda F, Moreno S, Pérez-Elías MJ, Casado JL, Antela A, Moreno A. Vascular disease in HIV-infected patients: a comparative study of two different therapeutic periods (1994-1997 versus 1998-2000). AIDS 2002;16:1971-3.
7. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002;25:1253-4.
8. Matetzky S, Domingo M, Kar S, Noc M, Shah PK, Kaul S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003;163:457-60.
9. Van der Valk M, Reiss P. Lipid profiles associated with antiretroviral drug choices. Curr Opin Infect Dis 2003;16:19-23.
10. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, D'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-93.